BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AGAH - ECPv5.16.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AGAH
X-ORIGINAL-URL:https://dev.agah.eu
X-WR-CALDESC:Veranstaltungen für AGAH
BEGIN:VTIMEZONE
TZID:Europe/Berlin
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20231215T160000
DTEND;TZID=Europe/Berlin:20231215T170000
DTSTAMP:20260929T015551
CREATED:20240610T171713Z
LAST-MODIFIED:20231107T093538Z
UID:6404-1702656000-1702659600@dev.agah.eu
SUMMARY:EUFEMEDs Innovation Club Webinar
DESCRIPTION:Online Christmas lecture: Axons Matter: Treating disorders of the central and peripheral nervous systems by targeting SARM-1 mediated axonal degeneration \n\n\n\n	INFORMATION \n\n\n\n\nSpeaker: Raul Krauss\, Ph.D. - Senior Vice President\, Co-Founder & Head of Biology\, Disarm Therapeutics\, a wholly owned subsidiary of Eli Lilly & Co \nAxonal degeneration is an early and ongoing event that causes disability and disease progression in many neurodegenerative disorders of the peripheral and central nervous systems. Small molecule SARM1 (sterile alpha and TIR motif containing 1) inhibitors have the potential to prevent axonal degeneration in peripheral and central axonopathies and to provide a transformational disease-modifying treatment for these disorders. This lecture will discuss the role of SARM1 in axonal degeneration\, and the discovery\, preclinical evaluation and first steps in early clinical development of small molecule SARM1 inhibitors. \nThis is the second of four 2023-2024 EUFEMED webinars. Dates for the other 2 webinars will be announced soon. \nMember tickets are available for members of: Association of Human Pharmacology in the Pharmaceutical Industry (AHPPI - UK)\, Healixia (Belgium)\, Association Française de Pharmacologie Translationnelle (AFPT – France)\, Association for Applied Human Pharmacology (AGAH - Germany)\, Associatie van Contract Research Organisaties in Nederland (ACRON - Netherlands)\, and Polish Federation for Early Medicines Development (Polfemed - Poland) \n\n\n\n\n\n\n\n\n	PROGRAMME AND REGISTRATION \nAxonal degeneration is an early and ongoing event that causes disability and disease progression in many neurodegenerative disorders of the peripheral and central nervous systems. Small molecule SARM1 (sterile alpha and TIR motif containing 1) inhibitors have the potential to prevent axonal degeneration in peripheral and central axonopathies and to provide a transformational disease-modifying treatment for these disorders. This lecture will discuss the role of SARM1 in axonal degeneration\, and the discovery\, preclinical evaluation and first steps in early clinical development of small molecule SARM1 inhibitors. \nREGISTRATION \nhttps://courses.2mpact.be/eufemed-2023-1512 \n\n\n\n\n	CONTACT \nResponsible for the program and performance \nEUFEMED\nRue de l’industrie 4\n1000 Brussels\nBELGIUM \ninfo@eufemed.eu\nwww.eufemed.eu \n 
URL:https://dev.agah.eu/event/eufemeds-innovation-club-webinar-2/
LOCATION:Webinar
CATEGORIES:Termine,Workshops
ORGANIZER;CN="EUFEMED":MAILTO:info@eufemed.eu
END:VEVENT
END:VCALENDAR